About this Research Topic
The newer generation of glucose-lowering agents, such as GLP-1 receptor agonists, enable many patients to reach glycaemic treatment goals, with cardiovascular risk reduction, and the additional benefit of significant weight reduction. Further improvements in glucose and weight management have been seen with the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist tirzepatide, which showed greater efficacy in lowering glycated haemoglobin (HbA1c) and bodyweight than GLP-1 receptor agonists. However, the controversy on the role of GIP on metabolic diseases still exists.
GIP has been proposed to be an adipogenic mechanisms and researchers focused to develop GIPR antagonists for the treatment of obesity. However, GIP is the main incretin to regulate insulin secretion postprandially. This issue will try to bring several opinions on this topic to increase the awareness on GIP's role on metabolic functions.
• How incretin-based theraupetics improved the management of diabetes and obesity.
• How GIP contributes: mechanistic insights and limitations with opinions from both camp
• How the field of management of metabolic disease evolves
Some editors in this collection are employed by Eli Lilly and Company, a firm involved in manufacturing medications aimed at incretin action.
GIP has been proposed to be an adipogenic mechanisms and researchers focused to develop GIPR antagonists for the treatment of obesity. However, GIP is the main incretin to regulate insulin secretion postprandially. This issue will try to bring several opinions on this topic to increase the awareness on GIP's role on metabolic functions.
• How incretin-based theraupetics improved the management of diabetes and obesity.
• How GIP contributes: mechanistic insights and limitations with opinions from both camp
• How the field of management of metabolic disease evolves
Some editors in this collection are employed by Eli Lilly and Company, a firm involved in manufacturing medications aimed at incretin action.
Keywords: Glucose-dependent insulinotropic polypeptide, Glucagon like peptide-1, Type 2 Diabetes, Obesity, Chronic Body Weight Management, Incretins
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
